Vries_et_al-2019-The_FEBS_Journal.pdf (4.19 MB)

Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity identifies differences in amino acid preferences between peptide-based substrates and covalent inhibitors.

Download (4.19 MB)
journal contribution
posted on 08.01.2020 by Laura E de Vries, Mateo I Sanchez, Katarzyna Groborz, Laurie Kuppens, Marcin Poreba, Christine Lehmann, Neysa Nevins, Chrislaine Withers-Martinez, David J Hirst, Fang Yuan, Shirin Arastu-Kapur, Martin Horn, Michael Mares, Matthew Bogyo, Marcin Drag, Edgar Deu
Malarial dipeptidyl aminopeptidases (DPAPs) are cysteine proteases important for parasite development thus making them attractive drug targets. In order to develop inhibitors specific to the parasite enzymes it is necessary to map the determinants of substrate specificity of the parasite enzymes and its mammalian homologue cathepsin C (CatC). Here, we screened peptide-based libraries of substrates and covalent inhibitors to characterize the differences in specificity between parasite DPAPs and CatC, and used this information to develop highly selective DPAP1 and DPAP3 inhibitors. Interestingly, while the primary amino acid specificity of a protease is often used to develop potent inhibitors, we show that equally potent and highly specific inhibitors can be developed based on the sequences of non-optimal peptide substrates. Finally, our homology modelling and docking studies provide potential structural explanations of the differences in specificity between DPAP1, DPAP3, and CatC, and between substrates and inhibitors in the case of DPAP3. Overall, this study illustrates that focusing the development of protease inhibitors solely on substrate specificity might overlook important structural features that can be exploited to develop highly potent and selective compounds. This article is protected by copyright. All rights reserved.

Funding

Crick (Grant ID: 10043, Grant title: Blackman FC001043) Wellcome Trust (Grant ID: 099950/B/12/Z, Grant title: WT 099950/B/12/Z)

History

Licence

Exports